ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/08/26	$0.000100	0.00%	6,623
28/07/26	$0.000100	0.00%	4,102

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 21:58:55 03/08/2026 +03			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.56M 3.33M 3.05M 5.76M 391M 5.86M 39.24M 15.37M 195M 15.4M 15.06M 643M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.13M -1.05M -965K -1.82M -124M -1.85M -12.4M -4.86M -61.59M -4.87M -4.76M -203M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
11/04/23	Insider Buy: Obseva	MT
06/04/23	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
31/03/23	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
31/03/23	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
22/03/23	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
15/03/23	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
13/03/23	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
13/03/23	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
13/03/23	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
13/03/23	ObsEva SA Announces Executive Changes	CI
03/03/23	Top Premarket Gainers	MT

30/08/22	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
01/08/22	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
29/07/22	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
03/06/22	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
26/04/22	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news : ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Course Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
31/03/23	ObsEva Files Year End 2022 Financial Statements	GL
23/03/23	OBSEVA SA : Other Events (form 8-K)	AQ
15/03/23	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

20/04/23	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
06/04/23	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
06/04/23	Bourse Zurich: ouverture en hausse avant le long week-end pascal
01/04/23	Obseva bleibt 2022 tief in den roten Zahlen
01/04/23	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.05
3 years	0		0.4
5 years	0		3.35
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/6/23 A	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
2/28/23 A	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
2/23/23 A	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	0.00%	0.00%	-	-99.80%	11.72K
WUXI APPTEC CO., LTD.	+0.05%	+3.08%	+38.17%	+66.77%	56.54B
ARGENX SE	-3.06%	-8.56%	+23.62%	+58.73%	53.6B
BIONTECH SE	+1.84%	+1.27%	-14.06%	-13.50%	22.91B
INSMED INCORPORATED	-0.15%	-6.00%	-9.42%	+344.47%	21.37B
GENMAB A/S	-0.67%	-3.25%	+33.09%	-29.84%	17.56B
PHARMAESSENTIA CORPORATION	+9.91%	-2.51%	+188.84%	+326.19%	13.53B
EXELIXIS, INC.	+3.83%	-1.34%	+47.77%	+165.22%	13.33B
ARROWHEAD PHARMACEUTICALS, INC.	+1.61%	+0.56%	+439.92%	+166.12%	11.92B
MADRIGAL PHARMACEUTICALS, INC.	+3.14%	-12.56%	+59.51%	+149.39%	10.8B
Average	+1.65%	-2.04%	+89.72%	+113.38%	22.16B
Weighted average by Cap.	+0.47%	-1.93%	+56.70%	+106.80%

	2021	2022
Net sales	-	19.64M 17.07M 15.93M 14.63M 27.58M 1.87B 28.06M 188M 73.58M 933M 73.76M 72.13M 3.08B
Net income	-58.38M -50.74M -47.37M -43.48M -81.99M -5.56B -83.42M -559M -219M -2.77B -219M -214M -9.15B	-29.88M -25.97M -24.24M -22.26M -41.97M -2.85B -42.7M -286M -112M -1.42B -112M -110M -4.68B
Net Debt	-28.08M -24.4M -22.78M -20.91M -39.43M -2.68B -40.12M -269M -105M -1.33B -105M -103M -4.4B	-5.4M -4.69M -4.38M -4.02M -7.58M -514M -7.71M -51.64M -20.22M -257M -20.27M -19.82M -846M